Standard BioTools Inc has a consensus price target of $2.37 based on the ratings of 4 analysts. The high is $3.25 issued by Jefferies on April 4, 2024. The low is $1.35 issued by TD Cowen on November 5, 2025. The 3 most-recent analyst ratings were released by TD Cowen on November 5, 2025, October 31, 2024, and August 1, 2024, respectively. With an average price target of $2.2 between TD Cowen, there's an implied 43.79% upside for Standard BioTools Inc from these most-recent analyst ratings.
1calculated from analyst ratings
| Get Alert | |||||
|---|---|---|---|---|---|
| Nov 5, 2025 | -11.76% | 1.351.55 | Previous Hold Current Hold | Get Alert | |
| Feb 27, 2025 | — | — | Previous Overweight Current Sector Weight | Get Alert | |
| Oct 31, 2024 | 63.4% | 2.52.75 | Previous Buy Current Buy | Get Alert | |
| Aug 1, 2024 | 79.74% | 2.753.5 | Previous Buy Current Buy | Get Alert | |
| Apr 16, 2024 | 128.76% | 3.5 | Previous Initiates Current Buy | Get Alert | |
| Apr 4, 2024 | 112.42% | 3.25 | Previous Initiates Current Buy | Get Alert | |
| Jul 12, 2023 | 161.44% | 4 | Previous Initiates Current Overweight | Get Alert |
The latest price target for Standard BioTools (NASDAQ:LAB) was reported by TD Cowen on November 5, 2025. The analyst firm set a price target for $1.35 expecting LAB to fall to within 12 months (a possible -11.76% downside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Standard BioTools (NASDAQ:LAB) was provided by TD Cowen, and Standard BioTools maintained their hold rating.
There is no last upgrade for Standard BioTools
The last downgrade for Standard BioTools Inc happened on February 27, 2025 when Keybanc changed their price target from N/A to N/A for Standard BioTools Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Standard BioTools, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Standard BioTools was filed on November 5, 2025 so you should expect the next rating to be made available sometime around November 5, 2026.
While ratings are subjective and will change, the latest Standard BioTools (LAB) rating was a maintained with a price target of $1.55 to $1.35. The current price Standard BioTools (LAB) is trading at is $1.53, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.